Nkarta Inc., a South San Francisco-based biopharmaceutical company, filed for its initial public offering on Friday.
It plans to list under the ticker…
“NKTX” on the Nasdaq Global Market.
The company is developing natural killer (NK)-based cell therapies that treat certain types of cancer, an approach similar to chimeric antigen receptors (CAR)-T therapies, of which two (Novartis’ NVS, -0.64% Kymriah and Gilead Sciences Inc.’s GILD, -1.05% Yescarta) have received approval from the Food and Drug Administration.
Nkarta, which has raised about $125 million in funding, according to Crunchbase, spent about $17 million on research and development last year and had a net loss of $21 million in 2019.
Investors include RA Capital, New Enterprise Associates, and Novo Holdings, which is part of the Novo Nordisk Foundation.
It plans to…
Continue reading at MARKETWATCH.com